SSG
STML

Summit Securities Group’s Stemline Therapeutics, Inc. STML Stock Holding History

Summit Securities Group’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-200
Closed -$4K – 679
2014
Q1 		$4K Buy
+200
New +$4.85K ﹤0.01% 329
2013
Q3 		– Sell
-50
Closed -$1K – 604
2013
Q2 		$1K Buy
+50
New +$796 ﹤0.01% 550

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $872M AUM 26.12% 1-Year Est. Return

Summit Securities Group's STML Position: Q2 2014 in Review

Summit Securities Group sold out of Stemline Therapeutics, Inc. (STML) in Q2 2014, closing a stake of 200 shares — an estimated $4K sold.

Summit Securities Group first reported a position in STML in Q2 2013 and held it in 2 quarters. The position peaked at $4K in Q1 2014. 61 funds tracked by Wall St. Rank hold STML as of Q2 2014.

  • Summit Securities Group reported no remaining Stemline Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • Summit Securities Group sold 200 Stemline Therapeutics, Inc. shares in Q2 2014, an estimated $4K.
  • Summit Securities Group first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 2 quarters.
  • Summit Securities Group's Stemline Therapeutics, Inc. position peaked at $4K in Q1 2014.
  • 61 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2014.

Based on Summit Securities Group's 13F filing for Q2 2014, filed 12 Aug 2014.